Editas Medicine Beheer

Beheer criteriumcontroles 2/4

De CEO Editas Medicine is Gilmore O’Neill, benoemd in Jun2022, heeft een ambtstermijn van 2.42 jaar. De totale jaarlijkse vergoeding van { bedraagt $ 2.39M, bestaande uit 26.8% salaris en 73.2% bonussen, inclusief aandelen en opties van het bedrijf. bezit rechtstreeks 0.13% van de aandelen van het bedrijf, ter waarde € 246.81K. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 1.7 jaar en 3.9 jaar.

Belangrijke informatie

Gilmore O’Neill

Algemeen directeur

US$2.4m

Totale compensatie

Percentage CEO-salaris	26.8%
Dienstverband CEO	2.4yrs
Eigendom CEO	0.1%
Management gemiddelde ambtstermijn	1.7yrs
Gemiddelde ambtstermijn bestuur	3.9yrs

Recente managementupdates

Recent updates

Analyse CEO-vergoeding

Hoe is Gilmore O’Neill's beloning veranderd ten opzichte van Editas Medicine's winst?
Datum	Totale vergoeding	Salaris	Bedrijfswinsten
Sep 30 2024	n/a	n/a	-US$211m
Jun 30 2024	n/a	n/a	-US$193m
Mar 31 2024	n/a	n/a	-US$166m
Dec 31 2023	US$2m	US$641k	-US$153m
Sep 30 2023	n/a	n/a	-US$195m
Jun 30 2023	n/a	n/a	-US$206m
Mar 31 2023	n/a	n/a	-US$219m
Dec 31 2022	US$9m	US$356k	-US$220m

Compensatie versus markt: De totale vergoeding ($USD 2.39M ) Gilmore } ligt boven het gemiddelde voor bedrijven van vergelijkbare omvang in de German markt ($USD 780.67K ).

Compensatie versus inkomsten: De vergoeding van Gilmore is het afgelopen jaar in lijn geweest met de bedrijfsprestaties.

CEO

Gilmore O’Neill (60 yo)

2.4yrs

Tenure

US$2,392,309

Compensatie

Dr. Gilmore O’Neill, M.B., M. M.SC., serves as Member of Scientific Advisory Board of AavantiBio, Inc. since February 2022. He is President & CEO of Editas Medicine, Inc. from June 01, 2022 and serves as i...

Leiderschapsteam

Naam	Positie	Tenure	Compensatie	Eigendom
Gilmore O’Neill	President	2.4yrs	US$2.39m	0.13% € 246.8k
Erick Lucera	CFO & Executive VP	1.5yrs	US$2.69m	0.028% € 52.6k
Linda Burkly	Executive VP & Chief Scientific Officer	1.3yrs	US$1.73m	0.018% € 32.9k
Baisong Mei	Executive VP & Chief Medical Officer	2.3yrs	US$1.14m	0.052% € 96.9k
Feng Zhang	Co-Founder & Scientific Advisory Board Member	11.8yrs	geen gegevens	geen gegevens
George Church	Co-Founder & Scientific Advisory Board Member	11.8yrs	geen gegevens	geen gegevens
Gregory Whitehead	Executive VP and Chief Technical & Quality Officer	less than a year	geen gegevens	geen gegevens
Cristi Barnett	Corporate Communications & Investor Relations	no data	geen gegevens	geen gegevens
Charlene Stern	Executive VP & General Counsel	no data	geen gegevens	geen gegevens
Linea Aspesi	Executive VP & Chief People Officer	1.7yrs	geen gegevens	geen gegevens
Caren Deardorf	Executive VP and Chief Commercial & Strategy Officer	1.2yrs	geen gegevens	geen gegevens

1.7yrs

Gemiddelde duur

60yo

Gemiddelde leeftijd

Ervaren management: Het managementteam van 8EM wordt niet als ervaren beschouwd (gemiddelde ambtstermijn 1.7 jaar), wat duidt op een nieuw team.

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
Gilmore O’Neill	President	no data	US$2.39m	0.13% € 246.8k
Feng Zhang	Co-Founder & Scientific Advisory Board Member	no data	geen gegevens	geen gegevens
George Church	Co-Founder & Scientific Advisory Board Member	no data	geen gegevens	geen gegevens
Emma Reeve	Independent Chairman of the Board	3.2yrs	US$238.24k	0% € 0
Andrew Hirsch	Independent Director	7.5yrs	US$210.56k	0.0024% € 4.5k
Jessica Hopfield	Independent Director	6.8yrs	US$231.07k	0.082% € 154.1k
Elliott Levy	Independent Director	1.6yrs	US$264.88k	0% € 0
David Scadden	Independent Director	5.8yrs	US$213.06k	0% € 0
Bernadette Connaughton	Independent Director	3.1yrs	US$215.06k	0% € 0
Meeta Chatterjee	Independent Director	3.9yrs	US$205.56k	0% € 0

3.9yrs

Gemiddelde duur

66yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van 8EM wordt beschouwd als ervaren (gemiddelde ambtstermijn 3.9 jaar).

Editas Medicine Beheer

Beheer criteriumcontroles 2/4

Belangrijke informatie

Recente managementupdates

Executive VP & Chief Scientific Officer recently sold €59k worth of stock

President recently sold €62k worth of stock

CFO & Executive VP recently sold €115k worth of stock

Independent Lead Director recently bought €235k worth of stock

Editas Medicine, Inc., Annual General Meeting, May 30, 2024

President recently sold €674k worth of stock

Recent updates

New major risk - Revenue and earnings growth

Third quarter 2024 earnings released: US$0.75 loss per share (vs US$0.55 loss in 3Q 2023)

Editas Medicine, Inc. Announces Achievement of in Vivo Preclinical Proof of Concept

New major risk - Revenue and earnings growth

Second quarter 2024 earnings released: US$0.82 loss per share (vs US$0.56 loss in 2Q 2023)

Executive VP & Chief Scientific Officer recently sold €59k worth of stock

New major risk - Share price stability

Editas Medicine Announces New Safety and Efficacy Data from the Edithal Trial of Reni-Cel in 7 Patients with Transfusion-Dependent Beta Thalassemia, Presented At the European Hematology Association (Eha) Annual Congress

President recently sold €62k worth of stock

CFO & Executive VP recently sold €115k worth of stock

Independent Lead Director recently bought €235k worth of stock

First quarter 2024 earnings released: US$0.76 loss per share (vs US$0.71 loss in 1Q 2023)

Editas Medicine, Inc., Annual General Meeting, May 30, 2024

President recently sold €674k worth of stock

Full year 2023 earnings released: US$2.02 loss per share (vs US$3.21 loss in FY 2022)

New major risk - Revenue and earnings growth

Editas Medicine, Inc. Announces New EDIT-301 Safety And Efficacy Data In 17 Patients, Presented At The American Society Of Hematology (ASH) Annual Meeting And In A Company-Sponsored Webinar

New major risk - Share price stability

Third quarter 2023 earnings released: US$0.55 loss per share (vs US$0.81 loss in 3Q 2022)

Editas Medicine, Inc. to Present Clinical Data from the Rubber and Edithal Trials of Edit-301 At the Ash 2023 Annual Meeting and in A Company-Sponsored Webinar

Editas Medicine, Inc. Announces Bruce E. Eaton Will Step Down as Chief Technology Officer and Chief Business Officer, Effective January 2, 2024

Editas Medicine, Inc. Appoints Caren Deardorf as Chief Commercial and Strategy Officer

Second quarter 2023 earnings released: US$0.56 loss per share (vs US$0.78 loss in 2Q 2022)

Editas Medicine, Inc. Announces Appointment of Linda C. Burkly as Executive Vice President and Chief Scientific Officer

New minor risk - Insider selling

New minor risk - Shareholder dilution

Editas Medicine, Inc. Announces Positive Initial Edit-301 Safety and Efficacy Data from the First Four Patients Treated in the Phase I/II Clinical Trial

Insider recently sold €58k worth of stock

Editas Medicine, Inc. Announces Management Changes

Editas Medicine, Inc. to Present Clinical Data from the RUBY Trial of EDIT-301 for the Treatment of Severe Sickle Cell Disease at the EHA 2023 Congress

First quarter 2023 earnings released: US$0.71 loss per share (vs US$0.74 loss in 1Q 2022)

Full year 2022 earnings released: US$3.21 loss per share (vs US$2.85 loss in FY 2021)

Shoreline Biosciences, Inc. entered into a definitive agreement to acquire Editas Medicine iNK cell franchise, EDIT-202 and certain related manufacturing technology from Editas Medicine, Inc.

Editas Medicine, Inc. Announces Step Down of Mark S. Shearman as Executive Vice President and Chief Scientific Officer, Effective March 31, 2023

Editas Medicine, Inc. Announces Positive, Initial Clinical Data from First Two Patients with Sickle Cell Disease Treated with EDIT-301 in Phase 1/2 RUBY Trial

Editas Medicine, Inc. Announces Clinical Data Demonstrating Proof of Concept of EDIT-101 from Phase 1/2 BRILLIANCE Trial

Third quarter 2022 earnings released: US$0.81 loss per share (vs US$0.57 loss in 3Q 2021)

Editas Reportedly in Talks to Sell Preclinical Oncology Assets

Editas Medicine, Inc. Presents Preclinical Data on Edit-103 for Rhodopsin-Associated Autosomal Dominant Retinitis Pigmentosa At the European Society of Gene and Cell Therapy Annual Meeting

Second quarter 2022 earnings released: US$0.78 loss per share (vs US$0.81 loss in 2Q 2021)

Editas Medicine, Inc. Announces Clinical Achievements in the Development of EDIT-301 for Sickle Cell Disease

Editas Medicine Appoints Baisong Mei, as Chief Medical Officer

First quarter 2022 earnings released: US$0.74 loss per share (vs US$0.86 loss in 1Q 2021)

Editas Medicine, Inc. Presents Preclinical Data on Edit-103 for Rhodopsin-Associated Autosomal Dominant Retinitis Pigmentosa At the Association for Research in Vison and Ophthalmology Conference

Editas Medicine, Inc. Announces Executive Changes, Effective June 1, 2022

Editas Medicine, Inc. Announces Dosing of First Pediatric Patient in the BRILLIANCE Clinical Trial of EDIT-101 for LCA10

Editas Medicine Reports Engineered iNK Cell Preclinical Data at American Association for Cancer Research Annual Meeting

Editas Medicine, Inc. Announces Favorable Decision from U.S. Patent and Trademark Office in CRISPR Patent Interference

Full year 2021 earnings: EPS in line with analyst expectations despite revenue beat

Editas Medicine, Inc. Terminates Lisa Michaels as Chief Medical Officer

Chairman recently sold €436k worth of stock

Editas Medicine Announces FDA Clearance of Investigational New Drug (IND) Application for EDIT-301 for the Treatment of Transfusion-Dependent Beta Thalassemia

Editas Medicine, Inc. Reports Preclinical Data Demonstrating Robust Tumor Reduction and Clearance Using Novel, Engineered iNK Cells at the American Society of Hematology Annual Meeting

Executive VP & Chief Medical Officer recently sold €52k worth of stock

Third quarter 2021 earnings released: US$0.57 loss per share (vs US$0.13 profit in 3Q 2020)

Chairman recently sold €452k worth of stock

Editas Medicine, Inc. Announces Initial Clinical Data from Clinical Trial of EDIT-101 for an Oral Presentation at the XIXth International Symposium on Retinal Degeneration

Editas Medicine, Inc. Presents Data on New Sleek Gene Editing Technology

Second quarter 2021 earnings released: US$0.81 loss per share (vs US$0.43 loss in 2Q 2020)

Editas Medicine Announces Enrollment of the First Pediatric Cohort in the Brilliance Clinical Trial of Edit-101 for the Treatment of Lca10 Following Idmc Endorsement

Editas Medicine Presents Preclinical Data Supporting the Initiation of the EDIT-301 Phase 1/2 RUBY Clinical Trial for the Treatment of Sickle Cell Disease at the European Hematology Association Congress

First quarter 2021 earnings released: US$0.86 loss per share (vs US$0.69 loss in 1Q 2020)

Chairman recently bought €958k worth of stock

Full year 2020 earnings released: US$1.98 loss per share (vs US$2.68 loss in FY 2019)

Revenue beats expectations

Editas Medicine Announces Update on Clinical Updates

Editas Medicine, Inc. Appoints James C. Mullen as President

President recently sold €70k worth of stock

Editas Medicine, Inc. Announces Management Changes, Effective February 15, 2021